Although the precise mechanisms through which P3H4 orchestrates these malignant processes require further investigation, particularly regarding its potential interplay with the PI3K/AKT pathway, our findings establish P3H4 as a promising therapeutic target and prognostic biomarker for HCC patients. This evidence concerns the gene AKT1 and hepatocellular carcinoma.